Twitter: @doctorpemm
Naveen Pemmaraju, MD
After completing his Internal Medicine training at Johns Hopkins, in the Osler Medical Program, Dr. Pemmaraju subsequently completed both hematology and oncology training at MD Anderson Cancer Center (MDACC). He was selected as a chief fellow in his second year of training. He obtained ABIM board certification in Internal Medicine, Hematology and Oncology, and continued his career at MDACC as an Assistant Professor in the Department of Leukemia.
In 2017, he was promoted to Associate Professor in the Department of Leukemia. He has an active clinical schedule during which he see patients: 2 full days of clinic per week, and 2 months of inpatient service per year. He has fellow teaching responsibilities as a Leukemia hematology/oncology Course Director and was the sole recipient of the MDACC Gerald P Bodey Award for Excellence in Education in 2020.
Dr. Pemmaraju’s clinical/translational research work has been focused on improving outcomes and developing novel therapies for patients with rare myeloid malignancies, including for adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Myeloproliferative Neoplasms (MPN) and Acute Myeloid Leukemia (AML). He has authored/co-authored over 250+ publications in the medical literature and has presented our group's work at national/international meetings: ASCO, ASH, EHA, AACR. Under the mentorship of Dr. Hagop Kantarjian, and Dr. Marina Konopleva, he has been able to establish his group's first active BPDCN clinic, which now serves as a nationwide referral base, and an active BPDCN research program with infrastructure and support for clinical and translational studies. Dr. Pemmaraju has been named as MDACC Department of Leukemia’s inaugural Director of BPDCN Program in 2020. He is the PI/co-PI of active clinical trials in the Leukemia department, for a translational sample study of patients with BPDCN, and was awarded a grant for identifying prognostic biomarkers in patients with BPDCN. He has developed key collaborative projects in BPDCN, MPN and AML, with clinical, hematopathology and dermatopathology teams; both internally and externally.